AU705732B2 - Streptococcal C5a peptidase vaccine - Google Patents

Streptococcal C5a peptidase vaccine Download PDF

Info

Publication number
AU705732B2
AU705732B2 AU15828/97A AU1582897A AU705732B2 AU 705732 B2 AU705732 B2 AU 705732B2 AU 15828/97 A AU15828/97 A AU 15828/97A AU 1582897 A AU1582897 A AU 1582897A AU 705732 B2 AU705732 B2 AU 705732B2
Authority
AU
Australia
Prior art keywords
lys
thr
asp
ala
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU15828/97A
Other languages
English (en)
Other versions
AU1582897A (en
Inventor
Paul P. Cleary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
University of Minnesota Twin Cities
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota Twin Cities, University of Minnesota System filed Critical University of Minnesota Twin Cities
Publication of AU1582897A publication Critical patent/AU1582897A/en
Application granted granted Critical
Publication of AU705732B2 publication Critical patent/AU705732B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/2111—C5a peptidase (3.4.21.110)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU15828/97A 1996-01-22 1997-01-21 Streptococcal C5a peptidase vaccine Expired AU705732B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/589756 1996-01-22
US08/589,756 US5846547A (en) 1996-01-22 1996-01-22 Streptococcal C5a peptidase vaccine
PCT/US1997/001056 WO1997026008A1 (en) 1996-01-22 1997-01-21 STREPTOCOCCAL C5a PEPTIDASE VACCINE

Publications (2)

Publication Number Publication Date
AU1582897A AU1582897A (en) 1997-08-11
AU705732B2 true AU705732B2 (en) 1999-05-27

Family

ID=24359391

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15828/97A Expired AU705732B2 (en) 1996-01-22 1997-01-21 Streptococcal C5a peptidase vaccine

Country Status (12)

Country Link
US (2) US5846547A (enExample)
EP (1) EP0877624B1 (enExample)
JP (1) JP4361606B2 (enExample)
KR (1) KR100582138B1 (enExample)
AT (1) ATE262924T1 (enExample)
AU (1) AU705732B2 (enExample)
CA (1) CA2243755C (enExample)
DE (1) DE69728380T2 (enExample)
DK (1) DK0877624T3 (enExample)
ES (1) ES2218656T3 (enExample)
PT (1) PT877624E (enExample)
WO (1) WO1997026008A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6676943B1 (en) 1997-04-24 2004-01-13 Regents Of The University Of Minnesota Human complement C3-degrading protein from Streptococcus pneumoniae
EP1051483A1 (en) * 1997-12-31 2000-11-15 Pincus, Seth H. A method of isolating a peptide which immunologically mimics microbial carbohydrates including group b streptococcal carbohydrates and the use thereof
KR20010089280A (ko) * 1998-09-24 2001-09-29 리전츠 오브 더 유니버스티 오브 미네소타 스트렙토코쿠스 뉴모니애로부터의 인간 보체 ｃ3 분해폴리펩티드
US7256265B2 (en) * 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
ES2330083T3 (es) * 2000-10-27 2009-12-04 Novartis Vaccines And Diagnostics S.R.L. Acidos nucleicos y proteinas de estreptococos de los grupos a y b.
AU2004226909B2 (en) * 2000-10-27 2008-02-07 J. Craig Venter Institute, Inc. Nucleic acids and proteins from streptococcus groups A & B
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20070053924A1 (en) * 2002-08-26 2007-03-08 Herve Tettelin Conserved and specific streptococcal genomes
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP2612679A1 (en) * 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
AU2005294275B2 (en) * 2004-10-08 2012-09-13 Glaxosmithkline Biologicals S.A. Immunogenic and therapeutic compositions for Streptococcus pyogenes
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2009030978A2 (en) * 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
US7364291B2 (en) * 2006-06-29 2008-04-29 Johnson & Johnson Vision Care, Inc. Contact lenses with light blocking rings
JP2010508276A (ja) * 2006-10-30 2010-03-18 ノバルティス アーゲー 化膿連鎖球菌のための免疫原性組成物および治療組成物
US20080311129A1 (en) * 2006-11-02 2008-12-18 Camas Incorporated Adherence inhibitor directed to and method of making and using
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
HU227970B1 (en) 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
NZ614064A (en) 2008-11-05 2015-04-24 Wyeth Llc Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
PL3170508T3 (pl) 2010-06-04 2020-04-30 Wyeth Llc Preparaty szczepionek
SI2608805T2 (sl) 2010-08-23 2025-09-30 Wyeth Llc Stabilne formulacije antigenov rLP2086 neisserie meningitidis
BR112013005329A2 (pt) 2010-09-10 2017-05-02 Wyeth Llc variantes não lipidadas de antígenos orf2086 de neisseria meningitidis
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
US9078842B2 (en) * 2011-10-26 2015-07-14 Wisconsin Alumni Research Foundation Peptide for reducing the phosphate requirement and excretion from farm animals
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX2018011291A (es) 2012-03-09 2023-01-31 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
EP2886140A1 (en) * 2013-12-17 2015-06-24 University of Limerick An apparatus for the extracorporeal treatment of blood
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10544197B2 (en) 2016-08-12 2020-01-28 Wisconsin Alumni Research Foundation FGF-23 epitope peptide for improving resistance to breakage and eggshell strength
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
AU2021368151B2 (en) 2020-10-27 2024-09-05 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
US20220387613A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2024521847A (ja) 2021-05-28 2024-06-04 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
JP2025537898A (ja) 2022-11-22 2025-11-20 ファイザー・インク コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454121A (en) * 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
US4695562A (en) * 1984-04-06 1987-09-22 Univ. Of Tennessee Research Corp. Synthetic peptide compounds
US4772584A (en) * 1986-05-23 1988-09-20 Cleary Paul P Inhibitor of C5a-mediated chemotaxis
US5124153A (en) * 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5162226A (en) * 1987-08-24 1992-11-10 University Of Tennessee Research Corp. (U.T.R.C.) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
DE68926427T2 (de) * 1988-03-25 1996-12-05 Univ Rockefeller Vom streptococcus m-protein abgeleitete synthetische peptide und damit hergestellte impfstoffe
EP0672123A1 (en) * 1992-01-08 1995-09-20 The Rockefeller University Multifunctional surface protein of streptococci
WO1993021220A1 (en) * 1992-04-08 1993-10-28 The Council Of The Queensland Institute Of Medical Research Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection
IL107025A0 (en) * 1992-09-16 1993-12-28 Univ Tennessee Res Corp Recombinant multivalent m protein vaccine
EP0618813B1 (en) * 1992-09-16 2002-01-09 The University Of Tennessee Research Corporation Antigen of hybrid m protein and carrier for group a streptococcal vaccine
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine

Also Published As

Publication number Publication date
CA2243755C (en) 2006-10-31
KR19990081863A (ko) 1999-11-15
EP0877624B1 (en) 2004-03-31
ATE262924T1 (de) 2004-04-15
PT877624E (pt) 2004-08-31
JP2000513709A (ja) 2000-10-17
CA2243755A1 (en) 1997-07-24
EP0877624A1 (en) 1998-11-18
WO1997026008A1 (en) 1997-07-24
JP4361606B2 (ja) 2009-11-11
ES2218656T3 (es) 2004-11-16
AU1582897A (en) 1997-08-11
DE69728380T2 (de) 2005-01-27
DK0877624T3 (da) 2004-06-21
US5846547A (en) 1998-12-08
KR100582138B1 (ko) 2006-08-30
US6270775B1 (en) 2001-08-07
DE69728380D1 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
AU705732B2 (en) Streptococcal C5a peptidase vaccine
US8440205B2 (en) Streptococcal C5A peptidase vaccine
Ji et al. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus
US7256265B2 (en) Streptococcal C5a peptidase vaccine